Highlights

Adjusted¹ EBIT increased by 11.3% to CHF 234.8 million. Adjusted¹ net profit from continuing operations increased by 3.0% to CHF 188.7 million. Thanks to the strong operating result, the Board of Directors will propose to the General Meeting a dividend of CHF 2.50 per share, which corresponds to an increase of 8.7%.

Highlights of the 2025 financial year

• The pharmacy network has developed dynamically through acquisitions, new openings and reorganisations.
• Demand for consultations has increased by almost 29%: 368,000 fee-based healthcare services were provided, including almost 93,000 vaccinations.
• Thanks to high demand for prescription-only medications, Galenica pharmacies grew organically by 3.3% and gained market share.
• In the Swiss consumer healthcare market, we further consolidated our leading position with sales growth of 6.2% to CHF 158.0 million.
• The “Services & Production” sector progressed positively and grew by 4%. All units – Bichsel, Lifestage and Medifilm – contributed to this growth. In 2025, Medifilm put another fully integrated blister packaging machine into operation and patient days once again increased significantly by 10%.
• With the acquisition of Labor Team in September 2025, Galenica was able to further broaden its value chain and significantly expand its range of services for physicians to include diagnostic services. The acquisition of Labor Team contributed around 1% to the Group’s sales growth.

• Strong sales growth of 4.8% was achieved in the “Wholesale” sector. Both the physicians segment with growth of 3.9% and the pharmacy segment with an increase of 5.3% performed in line with the market.
• HCI Solutions continues to make a major contribution to patient safety in Switzerland, registering 553 million CDS checks (+50%) on the Documedis^® platform in the reporting year.

¹⁾ See definition of adj. EBIT in the section “Alternative performance measures”.